These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16004562)

  • 1. The challenge of implementing high-throughput technologies in clinical trials.
    Mocellin S; Marincola FM
    Pharmacogenomics; 2005 Jun; 6(4):435-8. PubMed ID: 16004562
    [No Abstract]   [Full Text] [Related]  

  • 2. Bridging the gap between preclinical and clinical studies.
    Suckling K
    Curr Opin Investig Drugs; 2004 Sep; 5(9):928. PubMed ID: 15503645
    [No Abstract]   [Full Text] [Related]  

  • 3. Harnessing preclinical mouse models to inform human clinical cancer trials.
    Gutmann DH; Hunter-Schaedle K; Shannon KM
    J Clin Invest; 2006 Apr; 116(4):847-52. PubMed ID: 16585951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Control, drug preparation and dosage in the designing of experiments (author's transl)].
    Chen X
    Zhonghua Yi Xue Za Zhi; 1981 Jun; 61(6):335-8. PubMed ID: 6796231
    [No Abstract]   [Full Text] [Related]  

  • 5. [Extrapolation of experimental data on the methods for the clinical evaluation of drugs].
    Karkishchenko NN
    Farmakol Toksikol; 1982; 45(3):22-7. PubMed ID: 7095124
    [No Abstract]   [Full Text] [Related]  

  • 6. A semiparametric model for regression analysis of interval-censored failure time data.
    Finkelstein DM; Wolfe RA
    Biometrics; 1985 Dec; 41(4):933-45. PubMed ID: 3830259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remarks concerning new tools and methodologies for research and clinical practice.
    Kingston R
    Thromb Res; 2005; 117(1-2):119-21; discussion 145-51. PubMed ID: 16139871
    [No Abstract]   [Full Text] [Related]  

  • 8. Preclinical predictors of clinical safety: opportunities for improvement.
    Sistare FD; DeGeorge JJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical trials. Methodological principles and ethical aspects in the evaluation of therapies].
    Montagne O; Macquin-Mavier I; Lejonc JL
    Rev Prat; 1998 Mar; 48(6):679-84. PubMed ID: 9781143
    [No Abstract]   [Full Text] [Related]  

  • 10. Prospects for reform of the IND/NDA processes: part II.
    Romansky MA
    J Clin Psychopharmacol; 1982 Dec; 2(6):424-6. PubMed ID: 7174868
    [No Abstract]   [Full Text] [Related]  

  • 11. The Potential of Adaptive Design in Animal Studies.
    Majid A; Bae ON; Redgrave J; Teare D; Ali A; Zemke D
    Int J Mol Sci; 2015 Oct; 16(10):24048-58. PubMed ID: 26473839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The failure of torcetrapib: is there a case for independent preclinical and clinical testing?
    Doggrell SA
    Expert Opin Pharmacother; 2008 Apr; 9(6):875-8. PubMed ID: 18377331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
    Brodniewicz-Proba T
    Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Important issues in the design and reporting of clinical trials in severe sepsis and acute lung injury.
    Dellinger RP; Vincent JL; Marshall J; Reinhart K
    J Crit Care; 2008 Dec; 23(4):493-9. PubMed ID: 19056012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contribution of data of efficacy trials to judge the improvement of the medical usefulness of a drug].
    Bouvenot G; Eschwège E
    Therapie; 1992; 47(1):17-9. PubMed ID: 1523589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using imaging biomarkers to accelerate drug development and clinical trials.
    Pien HH; Fischman AJ; Thrall JH; Sorensen AG
    Drug Discov Today; 2005 Feb; 10(4):259-66. PubMed ID: 15708744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development plan: aspirin.
    Kelloff GJ; Crowell JA; Boone CW; Steele VE; Lubet RA; Greenwald P; Alberts DS; Covey JM; Doody LA; Knapp GG
    J Cell Biochem Suppl; 1994; 20():74-85. PubMed ID: 7616755
    [No Abstract]   [Full Text] [Related]  

  • 19. A systematic approach to preclinical and clinical safety biomarker qualification incorporating Bradford Hill's principles of causality association.
    Chetty RK; Ozer JS; Lanevschi A; Schuppe-Koistinen I; McHale D; Pears JS; Vonderscher J; Sistare FD; Dieterle F
    Clin Pharmacol Ther; 2010 Aug; 88(2):260-2. PubMed ID: 20592723
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical development plan: N-Acetyl-l-cysteine.
    Kelloff GJ; Crowell JA; Boone CW; Steele VE; Lubet RA; Greenwald P; Alberts DS; Covey JM; Doody LA; Knapp GG
    J Cell Biochem Suppl; 1994; 20():63-73. PubMed ID: 7616754
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.